PU.1 and Fli-I in Friend leukemia. Interestingly, we and others have found that Fli-1 is the 3' portion of a fusion transcript formed by the characteristic t( 1 1 ;22) in Ewing's sarcoma and ne~roepithelioma.'~*'* Thus, these ETS genes are both transcription factors and oncogenes.
Because developmental gene regulation is often controlled at the level of transcription," ETS domain proteins functioning as transcriptional activators may play a role in lineage commitment and stage progression during development. A first requirement of a candidate gene for controlling lineage choices is that its expression pattern should match the putative lineages it controls. One of the initial studies describing human PU. I reported that PU. I was expressed in all tissue^.^ On the contrary, in this study, PU.l was found to be expressed only in cells of hematopoietic origin. We used Northern analysis and in situ immunohistochemistry to show that PU.l expression is restricted to certain lineages and stages during blood cell development. Thus, PU. I can be considered a candidate for a genetic controller of the phenotypic cascades that occur during hematopoiesis.
MATERIALS AND METHODS
Human PU. I cloning. Human PU.1 was cloned from a X GTI 1 cDNA library made from the peripheral blood leukocytes of a patient with chronic myelogenous leukemia (CML). Mouse PU. l was used as a radiolabeled probe! The cDNA library, screening, and subcloning was performed as we described previously." The cDNA clone was dideoxy sequenced to ascertain that it indeed represented the full-length human PU. 1 cDNA as previously reported.' This probe was used in Northern analysis of the human cell lines.
Northern analysis. Poly A+ RNA was isolated from various cell lines and tissues using the Fasttrack kit from Invitrogen (San Diego, CA) according to the manufacturer's instructions. All cell lines were obtained from the American Type Culture Collection (Rockville, MD). Normal murine marrow macrophages were isolated as previously described" and treated with various differentiating agents as indicated. RNA was glyoxalated, electrophoresed in an agarose gel, and blotted to a nylon membrane. Hybridization took place at 42°C at a stringency of 4X SSPE and 40% formamide. The blots were washed at a final stringency of 65°C and 0.1X SSPE. All Northern analyses were stripped and reprobed with actin to asses the integrity and quantity of the loaded RNA.
PU.1 antisera was raised in rabbits against a 16 amino acid synthetic peptide from the amino terminus of mouse PU. 1. This antisera successfully binds to in vitrotranslated murine PU.1 and also pulls down murine cellular PU.I in immunoprecipitate reactions, as we previously reported." Immunohistochemistry was performed as we previously described. 23 In brief, decalcified and deparaffinized slides of normal mouse fe-In situ immunohistochemistry.
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mur marrow were covered with goat serum for 20 minutes, blotted, and then incubated overnight at 4°C with PU.1 antisera or preimmune sera. After two washes with phosphate-buffered normal saline (PBS), the slides were incubated with biotin-conjugated goat antirabbit antibody (30 minutes at 37°C; Kirkegaard and Perry, Gaithersberg, MD), washed twice with PBS. and then followed by Peroxidase-streptavidin (30 minutes at 37°C; Kirkegaard and Perry). The enzyme was developed with 3,Y-diaminobenzidine (DAB Sigma, St Louis, MO). Slides were counterstained with hematoxylin and mounted with glycerol-gelatin. These experiments were repeated three times with identical results.
RESULTS
Northern expression anal-vsis.
We first analyzed the expression of PU. I in a variety of hematopoietic and nonhematopoietic cell lines. Figure For personal use only. on August 30, 2017. by guest www.bloodjournal.org From transformed kidney, 833K fibroblasts, PANC 1 pancreatic carcinoma, MCF7 breast carcinoma, and TERA2 teratocarcinoma. Prolonged exposures of 2 weeks did not show any transcripts in these cells. Thus, PU. I is only expressed in cell lines of hematopoietic origin.
We originally discovered PU.1 because of its ability to bind to and activate promoters in B cells and macrophages. In this study, we next investigated the expression of PU.1 in normal murine marrow macrophages treated with various activating agents. Figure 2 shows marrow macrophages treated for 24 hours with either lipopolysaccharide LPS; 1 pg/mL), TPA (100 ng/mL), all-trans retinoic acid (2 X mol/L), A23 I87 (1 X mol/L), forskolin ( 1 X mol/ L), or interferon-? (300 IU/mL). Retinoic acid and interferon-? significantly reduce the level of PU. I expression. LPS and TPA slightly lower PU.1 expression. In situ immunohistochemical expression anal.vsis. We next examined the stage-and lineage-specific expression of PU. I in normal marrow using streptavidin-biotin peroxidase immunohistochemistry. The reactive PU. I antisera stains brown, whereas the hematoxylin counterstain is light blue. Figure 3 shows a representative photomicrogfaph of PU. 1 protein expression. First, PU. I expression is restricted to the nucleus, as would be expected for a transcription factor. Labeled in Although most lymphocytes seen in these marrow slides did not express PU.1 (labeled 5 in Fig 3) , there were a few that were positive for PU. I expression (Fig 4) . As Another interesting finding in all marrow slides examined was that PU.1 appeared to be expressed at its highest levels in dividing cells. An example of this can be seen in the metaphase cells in Fig 3 . This is the cell in the center of the figure with condensed chromatin. Figure 8 shows a cluster of eosinophilic precursors that all express PU.1 to some extent. Again, a mitotic cell is seen that highly expresses PU.1. Figure 9 shows an erythroid cluster in varying, but generally early, stages of develop ment. Notice that most still have nucleoli. They express PU. I at various levels. Thus, earlier erythroid cells express PU. I protein. Figure 7 has vascular endothelial cells that do not express PU. I.
Thus, these data indicate that PU.1 is located in the nucleus, as expected. In addition, PU. l is highly expressed in mitotic cells. PU. 1 is expressed in megakaryocytes. It is also expressed in granulocyte and erythroid precursors up to the myelocyte and basophilic normoblast. Metamyelocytes and polychromatophilic normoblasts are generally negative.
DISCUSSION
In this study, we investigated the expression of the ETS oncogene family member PU. I by Northern analysis and in situ immunohistochemistry. ETS family genes, including PU. I, are transcriptional activators.6*1s. 16 Because much of the phenotypic change that takes place during development is regulated at the transcriptional level, PU. I was assessed as a candidate for a regulator of lineage commitment and stage progression in hematopoiesis. Lineages or stages that PU. I is expressed in are the most likely to be regulated by its presence.
When we first cloned murine PU.1. it was found to be expressed in B cells and macrophages, but not in T cells! The report on the cloning of human PU. I showed evidence that it was ubiquit~us.~ When we cloned human PU.1, a preliminary Northern analysis showed that it was expressed only in cells of hematopoietic origin. Thus, this study was embarked upon to define the hematopoietic lineage and stage specificity of PU. I.
In the first portion of this study, PU.1 expression in a variety of hematopoietic and nonhematopoietic cell lines was analyzed by Northem blotting. PU.1 was expressed in myeloid and erythroid leukemia cell lines, but not in any of the IO nonhematopoietic lines assayed. It was not expressed in T cells, consistent with the data presented for mouse PU.l.6 In contrast, the related Fli-1 is expressed in human T cells.13 PU.1 was expressed in both the erythroleukemia cell lines K562 and HEL, whereas Fli-I is not expressed in K562 cells." Fli-1 is expressed only in FAB M6 human erythroleukemias, and not in any CML blast crisis erythroleuk- mias. These differences in expression could play a role in the different phenotypes of these leukemias.
B~~~~~~ PU, 1 was first defined as a transcriptional activastimulatory agents on norma1 marrow macrophages was studied. Retinoic acid, and interferon-y all reduced the level of PU. I expression. These agents share in common the effect that they stop macrophages from proliferating and stimulate their differentiation into a metabolically active phagocyte. Thus, PU. 1 expression seems to be restricted to proliferating, unactivated macrophages. In the second portion of this study, the expression of PU. I protein was studied in normal marrow using immunohisto- tor in monocyte/macrophage ce1l lines, the effect Of various PU, l-containing nuclei. Differences in the apparent size of cells bechemistry. It was found that PU. I was expressed in the nucleus of granulocyte and erythroid precursors, but not in the more mature stages of these lineages' development. A cunous exception to this was the finding that mature megakary- ocytes highly expressed PU. I. This is made more complex by the previous finding on Northern analysis that M07E megakaryocytic leukemia cells did not express PU.1 RNA. It is possible that PU. 1 protein expression is limited to later stages of megakaryocyte differentiation, unlike what is seen in erythroid or granulocyte development.
Interestingly, Gata-I, the zinc finger transcription factor important in erythroid development, is also seen in mature megakaryocytes," like PU. I. Also similar to PU. I, Gata-I is seen in developing erythrocytes. However, unlike PU.1, its expression increases with differentiation, rather than decreasing.
In addition, nonhematopoietic cells in the marrow such as osteocytes or endothelial cells did not express PU.1. Thus, based on its pattern of expression, PU.1 is a good candidate for transcriptionally activating lineage-or stagespecific phenotypic genes. In addition, the fact that PU.1 expression decreases as erythroid cells mature lends insight into the role it might play in Friend virus erythroleukemia. Friend virus insertionally activates the PU. I gene, destroying its normal regulation. Erythroblasts are then unable to turn off PU.1, which should decrease during maturation. These data imply that downregulation of PU.1 is an essential step in erythroid differentiation. Certainly, the finding that PU.1 protein was expressed at its highest level in mitotic cells should be pursued. Future cell elutriation studies looking at expression of PU. I during cell cycle stages could confirm our finding. PU. I may play a role in the transcriptional regulation of cell division. Indeed, there is recent evidence that PU.1 interacts with Rb, an important regulator of the cell cy~le.2~
Two recent findings lend evidence to the postulate that PU. I could be an important regulator of phenotypic change during hematopoietic differentiation. PU. I was found to activate the CDl lb promoter in cotransfection assaysz6 CDI Ib is an essential molecule in the adhesion of granulocytes and monocytes to endothelium for diapedesis. Its expression is turned on during granulocytic and monocytic development. In addition, PU. 1 is important in stimulating K Ig gene expression during B-cell devel~pment.~~.~' In this situation, PU.1 helps activate the K 3' enhancer. Thus, PU.1 probably plays a role in at least two important phenotypic changes during blood cell development.
Future investigation of phenotypic changes produced by forced PU.1 expression in normal marrow cells and cell lines will lend insight into the exact role PU. I plays in developing blood cells. The purpose of this study was to show that, contrary to previous reports, PU.1 is an excellent candidate for such a phenotypic regulator. For personal use only. on August 30, 2017. by guest www.bloodjournal.org From
